<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3315">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04322279</url>
  </required_header>
  <id_info>
    <org_study_id>C20-16</org_study_id>
    <secondary_id>2020-A00609-30</secondary_id>
    <nct_id>NCT04322279</nct_id>
  </id_info>
  <brief_title>Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. COVID19.</brief_title>
  <official_title>Factors Associated With a Positive SARS-CoV-2 Serology in Contact Subjects at High/Moderate Risk of Coronavirus SARS-CoV-2 Infection. (CoV-CONTACT-SERO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In December 2019, a pneumonia due to a novel coronavirus (SARS-CoV-2) emerged in the city of
      Wuhan, in China. In a few weeks, the number of confirmed cases of SARS-CoV-2 infection has
      dramatically increased, with almost 150'000 cases and more than 6'000 reported deaths on
      March, 16th 2020.

      Little is known on the rate of human-to-human transmission of this new coronavirus SARS-CoV-2
      in the community and within the hospital.

      Depending on the country, contact subjects considered to be at high or moderate risk of
      SARS-CoV-2 are, either isolated at home for a period of time defined by the health
      authorities or, on the contrary, continue their professional activity on the condition that
      they adopt measures to prevent transmission to those around them. In most European countries,
      healthcare workers adopt this second option. In all cases, it is most often recommended that
      contact persons monitor their state of health and communicate it to the persons dedicated to
      this action.

      Whether such subjects become spreaders of the virus is not known, nor is the proportion of
      viral spreader who will develop a symptomatic infection.

      In this study, we aim to evaluate the virological and clinical outcomes of subjects following
      a contact at high/moderate risk of SARS-CoV-2 acquisition, in community-subjects and/or
      healthcare workers.

      The study population is represented by all subjects who had a contact with
      laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at high/moderate
      risk of SARS-CoV-2 acquisition.

      This include both children and adult subjects, subject without social security, and
      healthcare workers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures added by the research:

      Blood sampling for determination of the presence of SARS-CoV-2 type M immunoglobulins or type
      G immunoglobulins.

      Blood sampling for whole exome sequencing
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 9, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with SARS-CoV-2 positive serology at day 30 following the last high/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case.</measure>
    <time_frame>30 days (+/-7)</time_frame>
    <description>Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Factors associated with a SARS-CoV-2 positive serology at day 30 (+/-7);</measure>
    <time_frame>30 days (+/-7)</time_frame>
    <description>Positive serology defined as the presence of SARS-CoV-2 IgM or IgG and assessed by ELISA, microneutralisation assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) between the first positive SARS-CoV-2 serology and the first negative SARS-CoV-2 serology.</measure>
    <time_frame>365 days (+/-30)</time_frame>
    <description>ELISA, microneutralisation assay</description>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Coronavirus</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serology</intervention_name>
    <description>SARS-CoV-2 serology</description>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Sequencing</intervention_name>
    <description>Whole exome sequencing</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is represented by all subjects who had a contact with
        laboratory-confirmed SARS-CoV-2 cases and whose contact was considered to be at
        high/moderate risk of SARS-CoV-2 acquisition.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  High/moderate risk contact with a laboratory-confirmed SARS-CoV-2 case;

          -  Within the 14 days following the last contact with a laboratory-confirmed SARS-CoV-2
             case;

          -  Obtaining informed consent.

        Exclusion Criteria:

          -  Subject included in the CoV-CONTACT study

          -  Subject deprived of freedom

          -  Subject under a legal protective measure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier DUVAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier DUVAL, MD</last_name>
    <phone>+33 1 40 25 71 48</phone>
    <email>xavier.duval@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bruno LINA, MD</last_name>
    <email>bruno.lina@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de maladies infectieuses et tropicales Hôpital Jean Minjoz CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CHIROUZE, MD</last_name>
      <phone>+ 33 3 81 21 85 33</phone>
      <email>catherine.chirouze@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des Maladies infectieuses et tropicales, Pôle Spécialités médicales, CHU Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Duc NGUYEN, MD</last_name>
      <phone>+33 5 56 79 21 73</phone>
      <email>duc.nguyen@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service des maladies infectieuses Hôpital Gabriel Montpied CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henri LAURICHESSE, MD</last_name>
      <phone>+33 4 73 93 71 49</phone>
      <email>hlaurichesse@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1432 Hôpital François Mitterrand CHU Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21 079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc BARDOU, MD</last_name>
      <phone>+33 380 393 433</phone>
      <email>marc.bardou@u-bourgogne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1406 CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean luc CRACOWSKI, MD</last_name>
      <phone>+33 4 76 76 92 60</phone>
      <email>JLCracowski@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique 1403 -CHU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique DEPLANQUE, MD</last_name>
      <phone>+33 3 20 44 68 91</phone>
      <email>dominique.deplanque@univ-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique Infectiologie Hôtel-Dieu CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Jacques KILADJIAN, MD</last_name>
      <phone>+33 1 42 49 94 94</phone>
      <email>jean-jacques.kiladjian@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation Clinique 1425, Hôpital Bichat Claude Bernard</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier DUVAL, MD</last_name>
      <phone>+33 1 40 25 71 48</phone>
      <email>xavier.duval@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin CIC 1417 Bâtiment Lavoisier</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odile LAUNAY, MD</last_name>
      <phone>+33 1 58 41 28 58</phone>
      <email>Odile.launay@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'investigation clinique 1414 Service de Pharmacologie clinique CHU Rennes Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno LAVIOLLE, MD</last_name>
      <phone>+33 2 99 28 96 68</phone>
      <email>bruno.laviolle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Félix Guyon Ile de la Réunion CHU nord</name>
      <address>
        <city>Saint Denis</city>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Léa BRUNEAU, MD</last_name>
      <phone>+262 2 62 90 68 83</phone>
      <email>lea.bruneau@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Département maladie infectieux CHU Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth BOTELHO-NEVERS, MD</last_name>
      <phone>+33 4 77 82 92 34</phone>
      <email>elisabeth.botelho-nevers@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique Ile de la Réunion CHU sud</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick GERARDIN, MD</last_name>
      <phone>+262 2.62.35.90.00</phone>
      <phone_ext>+ 5.42.71</phone_ext>
      <email>patrick.gerardin@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Investigation Clinique 1415 CHRU Tours - Hôpital Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie GISSOT, MD</last_name>
      <phone>+33 2 34 37 96 53</phone>
      <email>valerie.gissot@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Investigation Clinique 1433 CHRU de NANCY</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis GUILLEMIN, MD</last_name>
      <phone>+33 3 83 85 21 65</phone>
      <email>francis.guillemin@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service de Maladies infectieuses et tropicales Centre hospitalier</name>
      <address>
        <city>Cayenne</city>
        <zip>97306</zip>
        <country>French Guiana</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Félix DJOSSOU, MD</last_name>
      <phone>+594 5 94 39 50 40</phone>
      <email>felix.djossou@ch-cayenne.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>French Guiana</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 24, 2020</study_first_submitted>
  <study_first_submitted_qc>March 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact subject</keyword>
  <keyword>high/moderate risk of transmission</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

